Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
  • C07C323/43—Y being a hetero atom
  • C07C323/44—X or Y being nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
  • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
  • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
  • C07C317/42—Y being a hetero atom

Definitions

• This invention relates to novel phenylguanidines, to methods for preparing and using them, and to compositions containing them.
• Compounds of the invention have anthelmintic activity.
• X is a group NO 2 or NR 8 R 9 ,
• R is hydrogen, -OR 3 , -S(O) m R 3 , halogen or -CF3;
• R 1 is hydrogen
• R 2 is -SO 3 H, -OSO 3 H, -COOH, -PO 3 H 2 , or
• R 3 and R 4 are independently hydrogen, loweralkyl, loweralkoxyloweralkyl, hydroxyloweralkyl, cycloloweralkyl, phenyl or substituted phenyl, benzyl or substituted benzyl (wherein there are 1 , 2 or 3 substituents on the substituted phenyl or substituted benzyl selected independently from halogen, loweralkyl, loweralkoxy, haloloweralkyl, or loweralkoxyloweralkyl), or 5 or 6 membered heterocycles having 1 or 2 heteroatoms selected independently from oxygen, nitrogen and sulfur;
• R 5 , R 6 and R 7 are independently hydrogen, loweralkyl, loweralkoxyloweralkyl, hydroxyloweralkyl, phenyl or substituted phenyl, and benzyl or substituted benzyl (where there are 1, 2 or 3 substitutents on the substituted phenyl or substituted benzyl selected independently from halogen, loweral
• X is nitro, loweralkylcarbonylamino, phenylacetamido, benzamido, or benzamido substituted with loweralkyl or halogen, then R 2 is PO 3 H 2 or OPO 3 H 2 .
• This proviso preferably applies not only for the foregoing values of R and X but also when R is OR 5 (where R 5 is as defined above) and when X (independently of R) is NH 2 .
• lower alkyl means straight or branched alkyl chains of 1 to 6 carbon atoms, e.g. methyl, ethyl, n-propyl, n-butyl, iso-butyl, and hexyl.
• lower alkoxy means alkoxy groups having 1 to 6 carbon atoms, e.g. methoxy, ethoxy, propoxy, iso-butoxy, and pentoxy.
• Cycloloweralkyl means alkyl rings of 3 to 6 members, i.e. cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• Halogen means fluorine, chlorine, bromine and iodine.
• Haloloweralkyl means loweralkyl groups substituted by 1 to 3 halogen atoms, e.g. trifluoromethyl, dichloromethyl and chloroethyl.
• heterocycles defined in R 3 and R 4 are pyridine, furan, thiophene, pyrimidine, piperazine and thiazole. All positional isomers are contemplated, e.g., 2-, 3-, and 4-pyridine, 2- and 3-furan.
• the pharmaceutically acceptable salts contemplated include metal salts, e.g. alkali and alkali earth metal salts such as sodium, potassium and calcium, and other physiologically acceptable salts, e.g. trisamine, alkyl ammonium salts such as N- methylglucamine, ethanolamine, diethanolamine, triethanolamine, pyridinium and procaine, and tetraalkylammonium salts such as those produced with tetramethylammonium or tetraethylammonium ions. Also included within the scope of the invention are the tautomers at the guanidine group,
• Preferred compounds include those wherein R is a group CF 3 or R 3 SO m , where m and R 3 are as defined above; R 3 is preferably a lower alkyl group, expecially an n-propyl group, and m is preferably O.
• the group R (CF 3 or R 3 SO m ) is preferably at the 5-position.
• X is preferably NO 2 or NH 2 ; R 2 is preferably SO 3 H; n is preferably 2; and R 1 is preferably hydrogen or CONR 5 R 6 , especially wherein R 5 and R 6 are both lower alkyl, e.g. methyl groups.
• Representative preferred compounds include
• the compounds of the present invention exhibit useful anthelmintic activity while avoiding or reducing the disadvantages associated with known anthelmintics of the benzimidazole type, such as mebendazole, which are only sparingly water-soluble.
• Representative preferred compounds of its present invention have a water solubility of around 100 mg/ml or more compared with less than 1 mg/ml for mebendazole.
• the compounds of the invention can be prepared by standard methods for the preparation of such guanidine-type compounds. According to a further feature of the invention, we provide a process for the preparation of a compound or salt as defined above, which comprises reacting a compound of the formula
• a convenient intermediate for the preparation of compounds of formula I is an N-lower-alkoxycarbonyl-N'-[(2-X'-(4- or 5-)substituted)phenyl]-N"-(alkylacid)- guanidine, i.e. a compound of the formula
• N-Alkoxycarbonyl compounds of formula II can be hydrolyzed according to well known procedures (e.g. with a base such as sodium hydroxide in a solvent such as water or methanol) to prepare the corresponding guanidines (i.e. the -CO 2 R 7 group is replaced by H).
• Such guanidines can be treated with a diloweralkylcarbamyl chloride, e.g. dimethyl ⁇ arbamyl chloride, according to techniques known in the art to obtain the corresponding N-[diloweralkylcarbamyl]-N'- [(2-nitro-(4- or 5-) substituted)phenyl]-N"-(substituted alkyl)-guanidine.
• a diloweralkylcarbamyl chloride e.g. dimethyl ⁇ arbamyl chloride
• N-[Loweralkylcarbamyl]guanidines e.g. methylcarbamyl-guanidines
• N-[Loweralkylcarbamyl]guanidines can be prepared by treating guanidines having H instead of -CO 2 R 7 with potassium cyanate followed by alkylation with a diloweralkyl sulfate, e.g. dimethylsulfate, or with a lower alkyl halide, e.g. methyl chloride or methyl bromide.
• N-[loweralkylcarbamyl] guanidines can be prepared by treating guanidines having H instead of -CO 2 R 7 or the sodium salts thereof with an alkyl isocyanate.
• 2-Nitro compounds of formula II can be used as intermediates in well known reactions to prepare compounds of the present invention, i.e. compounds wherein the substituent at the 2- ⁇ osition in the phenyl ring is of the formula -NR 8 R 9 .
• (2-lower alkylamino-(4- or 5-) substituted phenyl) compounds may be prepared by hydro ⁇ genation (catalytic or chemical) of compounds of formula II, followed by alkylation with a di-lower alkyl sulfate or a lower alkyl halide as described above.
• the lower alkylamino compounds prepared as in the immediately preceding paragraph can be further alkylated with a di-lower alkyl sulfate or a lower alkyl halide to obtain the 2-di-loweralkylamino-(4- or 5-)substituted-phenyl compounds of formula I.
• the conversion of the 2-nitro compound to the corresponding 2-alkylamino or 2-dialkylamino compound can be carried out by hydrogenating the 2-nitro compound using an aliphatic aldehyde and platinum oxide as catalyst.
• an aliphatic aldehyde and platinum oxide as catalyst.
• formaldehyde in a 1:1 molar ratio to the nitro compound will yield the methylamine derivative
• formaldehyde in a 2:1 molar ratio will yield the dimethylamine compound.
• Compounds of formula I wherein one of R 8 and R 9 is lower alkyl and the other of R 8 and R 9 is lower alkoxycarbonyl can be prepared by the reaction of the appropriate 2-loweralkylamino-(4- or 5-) substituted- phenyl compound with the appropriately substituent acyl halide, e.g. methyl chloroformate, ethyl chloroformate, butyl chloroformate, 4-chlorophenyl chloroformate, 3-methylphenyl chloroformate, or 4-methoxyphenyl chloroformate.
• acyl halide e.g. methyl chloroformate, ethyl chloroformate, butyl chloroformate, 4-chlorophenyl chloroformate, 3-methylphenyl chloroformate, or 4-methoxyphenyl chloroformate.
• R 8 and R 9 are lower alkyl carbonyl or optionally substituted benzoyl
• R 8 and R 9 are lower alkyl carbonyl or optionally substituted benzoyl
• the appropriate carbonyl chloride e.g. benzoyl chloride or acetyl chloride
• 2-amino-(4 or 5-) substituted- phenyl compounds according to procedures known in the art.
• Compounds of formula II can be prepared by treating an appropriately substituted 2-X' -aniline with an alkoxycarbonyl-isothiocyanate, reacting the resulting product with a base such as sodium hydride or sodium methoxide and a dialkylsulfate or an alkylhalide to obtain the S-alkyl-isothiourea, and reacting this with an ⁇ -aminoalkylacid (e.g., taurine, 3-amino-1- ⁇ ropane- sulfonic acid, 2-aminoethylphosphoric acid or 4- aminobutyric acid) and a base such as sodium hydroxide.
• ⁇ -aminoalkylacid e.g., taurine, 3-amino-1- ⁇ ropane- sulfonic acid, 2-aminoethylphosphoric acid or 4- aminobutyric acid
• Preferred compounds of formula I wherein R is -S(O) m R 3 may be prepared by well known procedures from the corresponding -SR 3 compounds by treating the thio substituent with an oxidizing agent such as m-chloroperbenzoic acid, sodium m-periodate or hydrogen peroxide in acetic acid. Amino groups in the starting material may be protected during the oxidation by the addition of a reagent such as trifluoroacetic acid. Treatment with one equivalent of oxidizing agent will yield the -SOR 3 (sulfinyl) compound while treatment with two equivalents will yield the -SO 2 R 3 compound (sulfonyl). This oxidation may be carried out at one of several stages in the preparation of the compounds as shown below, wherein the preparation of a sulfinyl compound is described:
• nitro group can, of course, be replaced with any appropriate group comprised within X', especially and N-diloweralkyl group.
• 2-Amino-compounds of formula II can be prepared as follows: For example, 3,4-dinitrochlorobenzene may be treated with liquid ammonia in a solvent such as ethanol to obtain 2-nitro-5-chloro-aniline, which may then be treated with acetic anhydride in a solvent such as pyridine at 0-5°C to yield 2-nitro-5- chloroacetanilide. The 2-nitro-5-chloro acetanilide may then be converted to the corresponding 2-dialkylamino-5-chloroacetanilide by hydrogenating the nitro compound using platinum on carbon as catalyst in the presence of an aliphatic aldehyde (2:1 molar ratio to the nitro compound).
• the acetanilide can be hydrolyzed with a reagent such as sodium methoxide in a solvent such as methanol to give the corresponding 2-dialkylamino-5-chloroaniline.
• a reagent such as sodium methoxide in a solvent such as methanol
• the chloroaniline can be treated with an appropriate reagent to give a 2-dialkylamino-5- substituted-aniline, e.g. the chloroaniline reacted with 1-pro ⁇ anethiol and sodium hydroxide in dimethyl-formamide/water at room temperature will yield 2-dialkylamino-5-propylthioaniline.
• This aniline may then be treated as the compound of formula III in the foregoing reaction scheme to obtain a 2-dialkylaminocompound analogous to the compound of formula II.
• Metal salts, alkyl ammonium salts and other pharmaceutically acceptable salts may be prepared according to methods well known to those skilled in the art. The following examples illustrate the preparation of compounds and compositions of this invention.
• Method A Suspend the product of Example 1 (3.62 g) in anhydrous dimethylformamide (100 ml), add sodium methoxide (0.54 g) and warm gently with stirring to make a homogenous solution. Add N,N-dimethyl carbamoyl chloride and heat at 80oC for 8 hours. Cool the resultant mixture at room temperature, pour into water (100 ml) and stir 1 hour. Filter off the resulting solid, wash the filtrate with cold acetone and dry the filtrate to obtain the title compound.
• Method B Alternatively, the title compound may be prepared as follows:
• Example 3 Combine the product of Example 3 with sodium hydroxide in water and reflux for 4 hours. Cool the resulting solution and acidify to pH 1-2 with 10N aqueous hydrochloric acid. Filter the resulting precipitate, wash with cold water (3 x) then methanol (2 x) and dry to obtain the title compound.
• step B Slurry the product of step A (1.7 g) in ether (50 ml), add m-chloroperbenzoic acid (1.1 g of an 85% solution in 20 ml ether) and stir at room temperature 20 minutes. Extract the resultant solution with 5% aqueous sodium bicarbonate solution (3 x 50 ml), dry the organic phase over magnesium sulfate and evaporate the solvent. Purify the resultant crude product by chromatography and recrystallize the chromatographed product from ether to obtain N-methoxycarbonyl-N'-[(2-dimethylamino-5-propylsulfinyl)phenyl]-S-methyl isothiourea.
• the compounds of the present invention are useful in combatting helminthiasis, i.e. in treating animals, including humans, suffering from an infestation of parasitic worms, for example, roundworms, hookworms, whipworms or tapeworms, by administering to the host animal a therapeutic amount of a compound of the present invention.
• the compounds of this invention exhibit useful anthelmintic effects when administered to a host (e.g. a human, swine, dog, bird or ruminant) at doses as low as about one milligram per kilogram of body weight to about one hundred fifty milligrams per kilogram in a single day dosing or over several days, according to techniques well known in the art.
• a preferred method is to administer the compound at 5 to 25 milligrams per kilogram in a single dose.
• the compounds of this invention are non-toxic at the therapeutic dose.
• anthelmintic efficacy is assessed by determining the number of eggs in feces passed on the days following treatment with the compound compared with pretreatment days. Based on experimentation, proper dosages for curing various infections can be determined.
• Compounds of this invention may be administered in various formulations well known to those skilled in the human and veterinary medical arts, e.g., solutions, capsules, tablets and injectable preparations.
• the compounds may be administered as feed or drinking water additive preparations.
• the active ingredient is admixed with suitable sterile carriers such as sterile water and isotonic saline solution.
• Suitable clinical formulations containing the compounds of this invention can be administered orally in the form of tablets, capsules, elixirs and the like.
• the active compound is compounded with inert carriers such as, for example, gums, starches and sugars or it may be incorporated into gelatin capsules or formulated into elixirs which have the advantage of being amenable to manipulations in flavor by the addition of flavoring agents.
• Anthelmintic formulations particularly useful for, but not limited to, veterinary use comprise the compounds of this invention in ready to use liquid suspensions or wettable or water-dispersible powders which are dissolved in water prior to use.
• a liquid-suspension formulation may contain from 50 to 55% w./v. (grams/liters) of the active compound together with a dispersing agent and stabilizing agent.
• a typical formulation is as follows:
• Suitable dispersing agents are those containing sulphonate groups, for example sodium lignin sulphonate, or the sulphonated phenol, or naphthol formaldehyde polymers. Bentonite may be employed as the stabilizing agent, although it is possible to use such protective colloids as carboxymethyl cellulose, sodium alginate and the like.
• the formulations can be prepared by mixing the active compound and water containing dissolved dispersing agents very vigorously by means of suitable mechanical mixing equipment.
• a wettable or water-dispersible powder formulation may contain about 90 to 95% w./w. of the active compound together with a wetting agent and dispersing agent.
• a diluent such as kaolin can also be added if a concentration below about 98% w./w. is required.
• An anti-foaming agent and, in some cases, a stabilizing agent may be present.
• a typical formulation is as follows:
• Anti-foaming agent .urban. 0.01 to 1 by weight
• Suitable wetting agents are the non-ionic alkylphenolethylene oxide adducts , such as an octylphenol or nonylphenol condensed with ten moles of ethylene oxide, or anionic materials, such as the synthetic aryl alkyl sulphonates, or sodium dibutyl napthalene sulphonate. In general, about 1% w./w. wetting agent is required.
• the anti-foaming agent employed may be either a silicone or such materials as ethyl hexanol, octanol and the like; and the stabilizing agent may be chosen from bentonite or the water-soluble gums as discussed above.
• Wettable or water-dispersible powder formulations are prepared by careful and adequate mixing of the active compound with other ingredients with or without the addition of some water using typical powder blending equipment such as a ribbon blender. The powder is dissolved in water by the user before application in the field.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=27064684

Family Applications (2)

Family Applications After (1)

Country Status (3)

Families Citing this family (1)

Family Cites Families (1)

• 1984
  • 1984-09-21 EP EP19840903630 patent/EP0156889A1/de not_active Withdrawn
  • 1984-09-21 EP EP84111272A patent/EP0147537A1/de active Pending
  • 1984-09-21 WO PCT/EP1984/000293 patent/WO1985001283A1/en not_active Application Discontinuation
  • 1984-09-21 AU AU34381/84A patent/AU3438184A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events